Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Belite Bio, Inc - American Depositary Shares
(NQ:
BLTE
)
178.94
+1.36 (+0.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Belite Bio, Inc - American Depositary Shares
< Previous
1
2
3
4
Next >
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
Today 21:45 EDT
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
August 11, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
August 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
July 20, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
July 15, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
July 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
July 06, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
June 12, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 02, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
May 20, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
May 18, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
May 15, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
May 13, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
April 29, 2026
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
April 27, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
April 23, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio to Participate in Four Upcoming Investor Conferences
April 23, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
April 22, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
April 21, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 31, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Participate in the Leerink Global Healthcare Conference
March 02, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 02, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
February 23, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
January 29, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
January 27, 2026
From
Belite Bio, Inc
Via
GlobeNewswire
InvestorNewsBreaks – Belite Bio, Inc (NASDAQ: BLTE) Prices $350M Underwritten Public Offering of ADSs
December 05, 2025
Via
Investor Brand Network
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
December 01, 2025
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
December 01, 2025
From
Belite Bio, Inc
Via
GlobeNewswire
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
December 01, 2025
From
Belite Bio, Inc
Via
GlobeNewswire
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
November 10, 2025
From
Belite Bio, Inc
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
